OGOliver Gough

Oliver Gough

*This is an algorithmically generated author record based on publicly available information.

Oliver Gough has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Are entirely virus-free CAR T cells as good as lentiviral transduced universal cells?

    by Oliver Gough, Christos Georgiadis, Roland Preece, Renuka Kadirkamanathan, Waseem Qasim

  • A phase 1 feasibility trial of BE-CAR33, an “off-the-shelf” base-edited CAR33 T cell therapy for acute myeloid leukemia

    by Christos Georgiadis, Robert Chiesa, Hebatalla Rashed, Bethany K. Hughes, Roland Preece, Oliver Gough, Danielle Pinner, Stuart Adams, Rebecca Thomas, Annie Etuk, et al.

    Chimeric antigen receptor (CAR) T cell therapy for acute myeloid leukemia (AML) is constrained by antigen heterogeneity and shared expression with healthy compartments, and there are often challenges in obtaining autologous T cells from heavily pretreated patients. To address these challenges, we developed universal donor-derived, base-edited, anti-CD33 CAR T cells (BE-CAR33) that used precise multiplexed cytidine deamination to simultaneously disrupt the TRAC , CD52 , and CD7 loci to prevent graft-versus-host disease and evade immunotherapy effects. An open-label, nonrandomized, single-center phase 1 study (ISRCTN14430213) evaluated the safety, feasibility, and activity of BE-CAR33 cell therapy ahead of allogeneic stem cell transplantation (allo-SCT) for patients with AML. Eligible participants were aged less than 16 years with relapsed/refractory AML. Five patients were screened, and three were enrolled; one additional adult received BE-CAR33 through compassionate access. Participants received fludarabine, cyclophosphamide, and alemtuzumab followed by 1.2 to 1.8 × 10 6 BE-CAR33 cells per kilogram. Treatment-emergent adverse events included cytokine release syndrome (grade ≤2), neurotoxicity (grade 3), cytopenias (grade 4), and transient rashes. Two patients demonstrated reduced minimal residual disease and proceeded to allo-SCT. Serial flow cytometry, chimerism quantification, and vector copy number analyses tracked BE-CAR33 T cells until elimination during transplant. Differentially expressed genes included editing signatures and switched from manufacturing-related toward postexpansion effector and exhaustion profiles. Although primary end points were not met, this first-in-human study demonstrated the feasibility of an “off-the-shelf” base-edited CAR T cell approach and informs future multiantigen strategies against AML.


  • Open Access

    Are entirely virus-free CAR T cells as good as lentiviral transduced universal cells?

    by Oliver Gough, Christos Georgiadis, Roland Preece, Renuka Kadirkamanathan, Waseem Qasim

    Chimeric Antigen Receptor (CAR) T cells are now established as therapies for some haematological malignancies. While lentiviral or γ-retroviral vectors are commonly used for CAR delivery due to their efficiency and stable integration, supply constraints have created bottlenecks to wider applications and access. Alternatively, genome editing tools such as CRISPR-Cas9 can insert CAR genes by homology-directed repair (HDR) into specific genomic loci. ‘Universal’ donor CAR-T cells devoid of endogenous TCRαβ after CRISPR-Cas9-mediated editing of the T cell receptor alpha ( TRAC ) locus are being investigated for more cost-effective, ‘off-the-shelf’ therapies. Targeting insertion of CARs into the TRAC locus places transcription under the control of native regulatory machinery while simultaneously disrupting endogenous TCRαβ, and this has been reported to reduce exhaustion and extend persistence in modelling studies using humanised mice. We compared anti-CD20 CAR-T cells, generated with CAR inserts at either TRAC or CD3ζ loci using entirely virus-free manufacture, and universal CAR20-T cells generated using existing lentiviral procedures and CRISPR/Cas9 knockout. While non-viral cell yields were lower than lentiviral products cytotoxic function in vitro was comparable between groups. Studies in humanised murine models of leukaemia inhibition found non-viral CAR20-T cells were generally less efficacious than LV-CAR20 and exhibited more exhausted phenotypes. Non-viral approaches offer the prospect of sophisticated editing and precise CAR insertion but careful preclinical evaluation and well-designed clinical trials benchmarked against lentiviral approaches are recommended.

  • Open Access

    Base edited “universal” donor CAR T-cell strategies for acute myeloid leukaemia

    by Renuka Kadirkamanathan, Christos Georgiadis, Arnold Kloos, Akshay Joshi, Annie Etuk, Roland Preece, Oliver Gough, Axel Schambach, Martin Sauer, Michael Heuser, et al.

    Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T-cell approaches are under investigation, but high levels of disease heterogeneity remain a major hurdle to achieving durable responses. Targeting of multiple antigens may ensure complete immunological coverage of leukaemic blast populations, but such antigens are often also present on healthy haematopoietic populations. To address likely aplasia, strategies can be designed to bridge CAR T-cell therapies to allogeneic stem-cell transplantation (allo-SCT), as demonstrated in recent anti-CD7 CAR T-cell studies. Here we report that monotherapy using base edited “universal” donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of AML in immunodeficient mice when antigen expression was homogenous, but combined use of BE-CAR33 and BE-CARCLL-1 T cells was required to address heterogenous CLL-1 -/+ CD33 -/+ disease. We also demonstrate that removal of shared CD7 antigens enabled compatibility of BE-CAR33 and BE-CARCLL-1 with BE-CAR7 T cells, including in a patient-derived xenograft (PDX) model of AML. Therapeutic strategies envisage ‘pick and mix’ applications of base edited “universal” CAR T cells in combination determined by patient-specific antigen profiles. Such approaches also offer the possibility of deep, cell-based, de-bulking and conditioning ahead of allo-SCT and subsequent donor-derived reconstitution.


  • Open Access

    Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’ Immunotherapy

    by R. Preece, O. Gough, A. Joshi, R. Kadirkamanathan, E. Cudworth, D. Kallon, C. Georgiadis, W. Qasim

    Chimeric antigen receptor (CAR) T cell therapies are being widely investigated in both autologous and allogeneic settings, with gene editing providing new strategies to address barriers to mismatched cell therapies. Currently ‘universal’ donor derived T cell therapies require intensive lymphodepletion and are prone to host-mediated rejection. CD38, a transmembrane glycoprotein involved in cell activation and bioenergetics, is a promising immunotherapy target for haematological malignancies. Disruption of CD38 expression using base editing prevented fratricide between T cells expressing anti-CD38 CAR (CAR38). Additional base editing enabled generation of a ‘universal’ donor CAR38-T cells, devoid of endogenous TCRαβ and Human Leukocyte Antigen (HLA) molecules after disruption of T Cell Receptor Beta Constant ( TRBC ), Beta-2 microglobulin ( B2M ), and Regulatory Factor X5 ( RFX5 ). Removal of cell surface HLA expression enabled evasion of anti-HLA antibodies in sera from sensitised donors and reduced allo-stimulation in mixed lymphocyte cultures (MLCs), while TCRαβ disruption prevented allo-reactivity. In MLCs, CAR38 expression enabled potent ‘allo-defense’ activity against CD38 + allo-reactive cells. Multiplex-base-edited CAR38-T cells exhibited antigen-specific anti-leukemic activity against human B, T, and myeloid malignancies and inhibited disease progression in humanised murine xenograft models. CAR38-T cells offer a potent ‘off-the-shelf’ strategy against CD38 + haematological malignancies and plasma cells associated with autoimmunity.

  • Open Access

    Base edited “universal” donor CAR T cell strategies for acute myeloid leukaemia

    by Renuka Kadirkamanathan, Christos Georgiadis, Arnold Kloos, Annie Etuk, Roland Preece, Oliver Gough, Axel Schambach, Martin Sauer, Michael Heuser, Waseem Qasim

    Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T cell approaches are under investigation, but high levels of disease heterogeneity remain a major hurdle to achieving durable responses. Targeting of multiple surface antigens may ensure complete immunological coverage of leukemic blast populations, but such antigens are often also present on healthy haematopoietic populations. To address likely aplasia, strategies can be designed to bridge CAR T cell therapies to allogeneic stem cell transplantation (allo-SCT), as demonstrated in recent anti-CD7 CAR T cell studies. Here we report that monotherapy using base edited (BE) ‘universal’ donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of AML in immunodeficient mice when antigen expression was homogenous, but combined use of BE-CAR33 and BE-CARCLL-1 T cells was required to address heterogenous CLL-1 -/+ CD33 -/+ disease. We also demonstrate that removal of shared CD7 antigens enabled compatibility of BE-CAR33 with BE-CAR7 T cells, including in a patient-derived xenograft (PDX) model of AML. Therapeutic strategies envisage ‘pick and mix’ applications of base edited universal CAR T cells in combinations determined by patient-specific antigen profiles. Such approaches also offer the possibility of deep, cell-based, de-bulking and preparative conditioning ahead of allo-SCT followed by donor-derived reconstitution.


  • Open Access

    Dissection of a non-coding risk locus at 1p36.23 identifies ERRFI1 as a novel gene in the pathogenesis of psoriasis and psoriatic arthritis

    by Oliver J. Gough, Shraddha S. Rane, Amy Saunders, Megan Priestley, Helen Ray-Jones, Chenfu Shi, Richard B. Warren, Antony Adamson, Stephen Eyre

    Background: Psoriasis and its associated inflammatory arthritis Psoriatic Arthritis (PsA) are potentially life-ruining conditions associated with numerous comorbidities. A previously-identified genetic risk association for psoriasis and PsA lies in a non-coding region at chromosome 1p36.23, and as such functional validation is required to determine the genetic mechanism contributing to psoriatic disease risk. Results: rs11121131 – a variant in tight linkage with rs11121129, the lead GWAS variant for the 1p36.23 association – lies in a putative enhancer active in keratinocytes but not in immune cells. Promoter-capture Hi-C and H3K27Ac HiChIP showed keratinocyte-specific interactions between 1p36.23 and the TNFRSF9/PARK7/ERRFI1 gene locus ∼200Kb upstream of the risk locus. Deletion of the enhancer in HaCat keratinocytes led to a reduction in transcript levels of the gene ERRFI1 , a negative regulator of Epidermal Growth Factor Receptor (EGFR) signalling. CRISPR activation of the enhancer also affected ERRFI1 levels, but paradoxically showed that steady-state activation led to repression of ERRFI1 , accompanied by significant deposition of H3K27Me3 histone marks at both the enhancer and the ERRFI1 gene locus. ERRFI1 levels were shown to be increased in inflamed skin from a mouse model of psoriasis, further suggesting its involvement in disease. Conclusions: These data indicate rs11121131 lies in an enhancer which modulates ERRFI1 expression in keratinocytes, providing a likely risk mechanism for the 1p36.23 risk association. ERRFI1 represents a novel gene in the pathogenesis of psoriasis and PsA – improving our understanding of these diseases – and the ERRFI1/EGFR signalling axis may therefore be a target for new treatment modalities for psoriatic disease.


  • Open Access

    Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits

    by Chenfu Shi, Helen Ray-Jones, James Ding, Kate Duffus, Yao Fu, Vasanthi Priyadarshini Gaddi, Oliver Gough, Jenny Hankinson, Paul Martin, Amanda McGovern, et al.


  • Open Access

    An active chromatin interactome in relevant cell lines elucidates biological mechanisms at genetic risk loci for dermatological traits

    by Chenfu Shi, Helen Ray-Jones, James Ding, Kate Duffus, Yao Fu, Vasanthi Priyadarshini Gaddi, Oliver Gough, Jenny Hankinson, Paul Martin, Amanda McGovern, et al.

    Chromatin looping between regulatory elements and gene promoters presents a potential mechanism whereby disease risk variants affect their target genes. Here we use H3K27ac HiChIP, a method for assaying the active chromatin interactome in two cell lines: keratinocytes and skin derived CD8+ T cells. We integrate public datasets for a lymphoblastoid cell line and primary CD4+ T cells and identify gene targets at risk loci for skin-related disorders. Interacting genes enrich for pathways of known importance in each trait, such as cytokine response (psoriatic arthritis, psoriasis) and replicative senescence (melanoma). We show examples of how our analysis can inform changes in the current understanding of multiple psoriasis associated risk loci. For example, the variant rs10794648, which is generally assigned to IFNLR1 , was linked to GRHL3 in our dataset, a gene essential in skin repair and development. Our findings, therefore, indicate a renewed importance of skin related factors in the risk of disease. Abstract Figure: Graphical In this article we take disease associated variants from 5 dermatological conditions and use cell type specific datasets to map genes that could be affected by these variants, providing insight into disease mechanisms.


  • Open Access

    Chromatin-based techniques map DNA interaction landscapes in psoriasis susceptibility loci and highlight KLF4 as a target gene in 9q31

    by Helen Ray-Jones, Kate Duffus, Amanda McGovern, Paul Martin, Chenfu Shi, Jenny Hankinson, Oliver Gough, Annie Yarwood, Andrew P Morris, Antony Adamson, et al.

    Genome-wide association studies (GWAS) have uncovered many genetic risk loci for psoriasis, yet many remain uncharacterised in terms of the causal gene and their biological mechanism in disease. Here, we use a disease-focused Capture Hi-C experiment to link psoriasis-associated variants with their target genes in psoriasis-relevant cell lines (HaCaT keratinocytes and My-La CD8+ T cells). We confirm previously assigned genes, suggest novel candidates and provide evidence for complexity at psoriasis GWAS loci. In the 9q31 risk locus we combine further epigenomic evidence to demonstrate how the psoriasis association forms a functional interaction with the distant (>500 kb) KLF4 gene. We use CRISPR activation coupled with RNA-seq to demonstrate how activation of psoriasis-associated enhancers upregulates KLF4 in HaCaT cells. Our study design provides a robust pipeline for following up on GWAS disease-associated variants, paving the way for functional translation of genetic findings into clinical benefit.